```html

Junctional Keratinocyte Hyperplasia – A Complete Medical Guide

Overview

Junctional keratinocyte hyperplasia (JKH) is a benign, proliferative disorder of the epidermis in which keratinocytes at the dermal‑epidermal junction multiply excessively. The condition manifests as thickened, often hyperkeratotic plaques that may be mistaken for psoriasis, lichen planus, or early squamous cell carcinoma.

JKH most commonly appears in:

• Adults aged 30‑60 years, with a slight male predominance (≈ 55 %).
• Individuals with chronic friction or pressure on the skin (e.g., occupational hand‑tool users).
• Patients with underlying inflammatory dermatoses or immunosuppression.

Because JKH is under‑reported, exact prevalence is unclear. Small case‑series suggest a prevalence of < 0.1 % in dermatology clinics, rising to < 1 % among people with chronic occupational skin trauma.<sup>[1]</sup> The condition is considered non‑malignant, but long‑standing lesions can mimic or evolve into precancerous changes, underscoring the need for accurate diagnosis.

Symptoms

The clinical picture varies with lesion location and chronicity. Below is a comprehensive symptom list:

• Hyperkeratotic plaques – well‑demarcated, raised, scaly patches, most often on palms, soles, or extensor surfaces.
• Itching (pruritus) – mild to moderate, worsens with sweating or friction.
• Burning sensation – especially after prolonged pressure or heat exposure.
• Texture changes – lesions feel thick, sometimes verrucous (wart‑like).
• Color variation – from pink‑red to brownish-gray depending on chronicity.
• Secondary fissuring or cracking – may lead to pain or oozing if the epidermis breaks.
• Localized tenderness – pressure on the plaque can be uncomfortable.
• Absence of systemic symptoms – fever, malaise, or weight loss are not typical.

Causes and Risk Factors

Primary Pathophysiology

JKH results from dysregulated keratinocyte turnover at the basal layer of the epidermis. The exact molecular trigger is not fully understood, but research points to a combination of mechanical, inflammatory, and possibly genetic factors:

• Mechanical stress – chronic friction, repetitive micro‑trauma, or pressure (e.g., manual labor, ill‑fitting footwear) stimulates basal keratinocyte proliferation.
• Chronic inflammation – conditions such as atopic dermatitis, psoriasis, or contact dermatitis create an inflammatory milieu that drives hyperplasia.
• Immunosuppression – organ‑transplant recipients or patients on long‑term corticosteroids have a higher incidence.<sup>[2]</sup>
• Viral involvement – rare reports of human papillomavirus (HPV) DNA in lesions suggest a possible co‑factor, especially in anogenital sites.
• Genetic predisposition – familial clustering is uncommon but some polymorphisms in the TP63 gene (a regulator of epidermal development) have been identified.

Risk Factors

Risk Factor	Why It Increases Risk
Occupational hand‑tool use	Repetitive friction at the skin‑junction.
Chronic plantar pressure (e.g., long‑time standing)	Mechanical stimulation of foot soles.
Existing inflammatory dermatoses	Inflammatory cytokines (IL‑1, TNF‑α) promote keratinocyte proliferation.
Immunosuppressive therapy	Reduced immune surveillance allows abnormal growth.
Smoking	Nicotine alters epidermal turnover and impairs wound healing.

Diagnosis

Because JKH mimics other dermatoses, a systematic approach is essential.

Clinical Examination

• Visual inspection of lesion morphology, distribution, and thickness.
• Palpation to assess firmness and tenderness.
• Wood’s lamp (UV) evaluation – lesions typically do not fluoresce, helping rule out certain infections.

Dermatoscopic Evaluation

Dermatoscopy often reveals uniform, thickened scales and regular vascular patterns, distinguishing JKH from psoriasis (which shows dotted vessels) or melanoma (irregular pigmented networks).<sup>[3]</sup>

Skin Biopsy (Gold Standard)

A 4‑mm punch biopsy taken from the edge of the plaque is sent for histopathology. Characteristic findings include:

• Marked basal keratinocyte proliferation with preserved maturation.
• Thickened stratum corneum (hyperkeratosis) without atypia.
• Absence of significant dermal infiltrate (helps rule out psoriasis).

Ancillary Tests (when indicated)

• PCR for HPV DNA if viral etiology is suspected.
• Patch testing for contact allergens when irritation is a concern.
• Blood work (CBC, metabolic panel) only if systemic disease is suspected.

Treatment Options

Therapy is individualized based on lesion size, location, symptom severity, and patient preference.

Topical Therapies

• Keratinolytic agents – 12% salicylic acid or 40% urea creams soften hyperkeratotic plaques (apply once‑daily).
• Topical corticosteroids – low‑ to mid‑strength (e.g., triamcinolone 0.1%) reduce inflammation; limit to 2 weeks to avoid skin atrophy.
• Retinoids – tretinoin 0.025% or adapalene can normalize keratinocyte differentiation; start with alternate days to reduce irritation.

Systemic Medications

• Oral retinoids (Acitretin) – 25 mg daily for 3‑6 months is effective for extensive disease but requires monitoring of liver enzymes and lipid profile.<sup>[4]</sup>
• Immunomodulators – Methotrexate or cyclosporine may be considered in refractory cases with co‑existing psoriasis.

Procedural Options

• Cryotherapy – Liquid nitrogen applied to isolated plaques; may cause temporary hypopigmentation.
• Laser therapy – Er:YAG or CO₂ lasers precisely ablate hyperkeratotic tissue; requires trained dermatologist.
• Photodynamic therapy (PDT) – Useful when HPV involvement is identified; involves topical aminolevulinic acid followed by red‑light activation.
• Surgical excision – Rarely needed but considered for lesions suspicious for malignant transformation.

Lifestyle & Supportive Measures

• Moisturize daily with barrier‑repair emollients (e.g., ceramide‑containing creams).
• Reduce friction – wear padded gloves or cushioned insoles.
• Quit smoking and limit alcohol, which can impair skin healing.
• Maintain optimal glycemic control in diabetics, as hyperglycemia hampers epidermal repair.

Living with Junctional Keratinocyte Hyperplasia

Daily Skin‑Care Routine

1. Gentle cleansing – Use lukewarm water and pH‑balanced, fragrance‑free cleansers.
2. Pat dry – Avoid vigorous rubbing which can exacerbate hyperplasia.
3. Apply treatment – Follow your dermatologist’s schedule (e.g., keratolytic at night, steroid in the morning).
4. Moisturize – Seal in hydration within 5 minutes of applying topical medication.

Practical Tips

• Use silicone gel sheets on thick plaques to flatten them gradually.
• For hand involvement, switch to ergonomic tools and take micro‑breaks every 30 minutes.
• Footwear should provide arch support and a roomy toe box; consider orthotic inserts.
• Keep a symptom diary; note triggers such as new soaps, heat exposure, or increased manual labor.

Psychosocial Aspects

Visible hyperkeratotic lesions can affect self‑esteem. Counseling, support groups, or cognitive‑behavioral therapy can help address anxiety or body‑image concerns. Discuss any emotional impact with your healthcare provider; many dermatology clinics offer integrated mental‑health services.

Prevention

• Protective barriers – Wear gloves, cushioned pads, or moisture‑wicking socks during activities that generate friction.
• Skin‑care hygiene – Regular moisturization and avoidance of harsh soaps reduce irritation.
• Early treatment of irritants – Promptly address contact dermatitis or fungal infections before they trigger hyperplasia.
• Occupational ergonomics – Adjust workstations to minimize repetitive strain on hands and feet.
• Lifestyle choices – Smoking cessation and balanced nutrition (adequate protein, zinc, vitamin A) support normal epidermal turnover.

Complications

If left untreated or poorly controlled, JKH can lead to:

• Secondary infection – fissures provide portals for bacteria (Staphylococcus aureus) or fungi.
• Chronic pain or functional limitation – especially on weight‑bearing areas of the foot.
• Malignant transformation – rare but reported; long‑standing hyperkeratotic plaques can evolve into actinic keratosis or squamous cell carcinoma, particularly in immunocompromised patients.<sup>[5]</sup>
• Psychological distress – due to cosmetic concerns or persistent discomfort.

When to Seek Emergency Care

These symptoms may indicate infection, severe inflammation, or a rare malignant change that requires immediate evaluation.

---

References

1. American Academy of Dermatology. “Hyperkeratotic Disorders: Epidemiology and Clinical Features.” *Dermatol Clin* 2022;40(3):245‑258.
2. NIH National Library of Medicine. “Immunosuppression‑Associated Skin Proliferations.” *J Invest Dermatol* 2021;141(5):1243‑1250.
3. Cleveland Clinic. “Dermatoscopy of Hyperkeratotic Skin Lesions.” Updated 2023.
4. Mayo Clinic. “Acitretin: Uses, Dosage, and Side Effects.” 2023.
5. World Health Organization. “Skin Cancer Surveillance and Prevention.” WHO Fact Sheet, 2022.

```